Missing/wrong data?
Log in to edit
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
scientific article published on 6 January 2018
Author/s
author: Peter Bossuyt, Benjamin Pariente, Laurent Peyrin-Biroulet, Geert D'Haens, Séverine Vermeire, Edouard Louis
Work details
Publication date
January 6, 2018
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.